Logo-bi
BioImpacts. 2021;11(4): 281-287. doi: 10.34172/bi.2021.10
PMID: 34631490        PMCID: PMC8494255

Short Communication

Evaluation of in-situ gel-forming eye drop containing bacteriophage against Pseudomonas aeruginosa keratoconjunctivitis in vivo

Golnar Rahimzadeh 1 ORCID, Majid Saeedi 2, Ali Nokhodchi 3 * ORCID, Mahmood Moosazadeh 4, Maryam Ghasemi 5, Seyyed Sohrab Rostamkalaei 6, Parham Mortazavi 7, Mohammad Eghbali 7, Reza Pourbakhshian 7, Mohammad Sadegh Rezai 1 * ORCID, Ebrahim Nemati Hevelaee 8

Cited by CrossRef: 7

1- Mursalin M, Astley R, Coburn P, Bagaruka E, Hunt J, Fischetti V, Callegan M, Dunman P. Therapeutic potential of Bacillus phage lysin PlyB in ocular infections . mSphere. 2023;8(4) [Crossref]
2- Abdelrahman F, Makky S, Teba H, Agwa M, Abd ElAziz M, Awad R, Hassan Y, Abdelsattar A, Connerton I, El-Shibiny A. Potential of vB_Pa_ZCPS1 phage embedded in situ gelling formulations as an ocular delivery system to attenuate Pseudomonas aeruginosa keratitis in a rabbit model. Journal of Controlled Release. 2025;380:52 [Crossref]
3- Patil R, Dehari D, Chaudhuri A, Kumar D, Kumar D, Singh S, Nath G, Agrawal A. Recent advancements in nanotechnology-based bacteriophage delivery strategies against bacterial ocular infections. Microbiological Research. 2023;273:127413 [Crossref]
4- Jeang L, Tuli S. Therapy for contact lens-related ulcers. 2022; [Crossref]
5- Tribin F, Lieux C, Maestre-Mesa J, Durkee H, Krishna K, Chou B, Neag E, Tóthová J, Martinez J, Flynn H, Parel J, Miller D, Amescua G. Clinical Features and Treatment Outcomes of Carbapenem-Resistant Pseudomonas aeruginosa Keratitis. JAMA Ophthalmol. 2024;142(5):407 [Crossref]
6- Sharma Y, Chahar K, Mishra L, Kumari L, Singla A, Patel P, Singh D, Kurmi B. Recent overviews on the drug delivery aspects and applications of brinzolamide for the management of glaucoma. Health Sciences Review. 2023;6:100083 [Crossref]
7- Bakhrushina E, Mikhel I, Kondratieva V, Demina N, Grebennikova T, Krasnyuk Jr I, Krasnyuk I. Main Aspects of Pharmaceutical Development of In situ Immunobiological Drugs for Intranasal Administration. CPB. 2024;25(11):1394 [Crossref]
8- André C, Medina M, Kolenda C, Blazière L, Helluin E, Resch G, Bispo P, Laurent F. In Vitro Activity of Bacteriophages Against Ocular Methicillin-resistant S. aureus Isolates Collected in the US. Ophthalmol Ther. 2025;14(5):897 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of COPE
Follower of ICMJE
Permission: Creative Commons